Mind Medicine (MindMed) (MNMD) to Release Earnings on Wednesday

Mind Medicine (MindMed) (NASDAQ:MNMD - Get Free Report) is scheduled to be posting its quarterly earnings results after the market closes on Wednesday, May 8th. Analysts expect Mind Medicine (MindMed) to post earnings of ($0.66) per share for the quarter. Investors that are interested in participating in the company's conference call can do so using this link.

Mind Medicine (MindMed) (NASDAQ:MNMD - Get Free Report) last released its quarterly earnings data on Wednesday, February 28th. The company reported ($0.59) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.11). On average, analysts expect Mind Medicine (MindMed) to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Mind Medicine (MindMed) Stock Performance

Shares of NASDAQ:MNMD traded up $0.48 during trading on Friday, hitting $10.00. 1,087,098 shares of the stock traded hands, compared to its average volume of 1,841,036. The company has a quick ratio of 3.22, a current ratio of 3.22 and a debt-to-equity ratio of 0.18. The company has a fifty day moving average price of $8.83 and a two-hundred day moving average price of $5.33. Mind Medicine has a 52-week low of $2.41 and a 52-week high of $12.22. The company has a market cap of $702.70 million, a price-to-earnings ratio of -4.15 and a beta of 2.72.

Insider Activity at Mind Medicine (MindMed)

In other news, insider Dan Karlin sold 6,578 shares of the company's stock in a transaction on Monday, March 25th. The shares were sold at an average price of $9.50, for a total transaction of $62,491.00. Following the completion of the sale, the insider now owns 358,452 shares of the company's stock, valued at $3,405,294. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In related news, CEO Robert Barrow sold 16,519 shares of the company's stock in a transaction dated Monday, March 25th. The shares were sold at an average price of $9.50, for a total value of $156,930.50. Following the completion of the sale, the chief executive officer now owns 580,202 shares of the company's stock, valued at $5,511,919. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Dan Karlin sold 6,578 shares of the firm's stock in a transaction dated Monday, March 25th. The stock was sold at an average price of $9.50, for a total transaction of $62,491.00. Following the sale, the insider now owns 358,452 shares of the company's stock, valued at $3,405,294. The disclosure for this sale can be found here. 2.11% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

MNMD has been the subject of a number of analyst reports. Leerink Partnrs reiterated an "outperform" rating on shares of Mind Medicine (MindMed) in a research report on Monday, April 15th. Royal Bank of Canada boosted their price objective on Mind Medicine (MindMed) from $14.00 to $15.00 and gave the company an "outperform" rating in a research report on Thursday, February 29th. HC Wainwright reiterated a "buy" rating and set a $75.00 target price on shares of Mind Medicine (MindMed) in a research report on Thursday, March 14th. Finally, SVB Leerink started coverage on shares of Mind Medicine (MindMed) in a research note on Monday, April 15th. They issued an "outperform" rating and a $20.00 price target on the stock. Six analysts have rated the stock with a buy rating, According to data from MarketBeat, Mind Medicine (MindMed) currently has an average rating of "Buy" and a consensus target price of $25.20.

Mind Medicine (MindMed) Company Profile

Mind Medicine (MindMed) Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder.